Rapid Glioma Analysis Could Help Guide Brain Tumor Surgery

Using a rapid mass spectrometry workflow, researchers identified molecular differences among brain tumors

October 8, 2026
3 min

The Analytical Scientist

Overview

A study reported that syringe touch spray tandem mass spectrometry analyzed brain tissue in approximately three minutes and distinguished glioma from nontumor tissue while classifying tumors by IDH status and grade. In 86 human specimens, selected metabolite ratios showed high diagnostic performance, but mixed-tissue experiments indicated that tumor-core thresholds may not reliably identify cancer at heterogeneous surgical margins.

Background

Gliomas may extend beyond margins visible on imaging, complicating efforts to remove tumor while preserving healthy brain tissue. Molecular classification is clinically relevant, but the article notes that molecular test results are generally unavailable until after surgery. The reported assay was developed to provide molecular information during surgery, rather than to replace standard intraoperative care. Contemporary glioma classification uses integrated histomolecular diagnoses, including IDH status and, where applicable, 1p/19q codeletion.

Data Highlights

Measure	Reported result
Analysis time	Approximately 3 minutes
Specimens analyzed	86 total: 78 glioma and 8 nontumor
N-acetylaspartate-to-carnitine ratio for glioma versus nontumor tissue	97% sensitivity, 100% specificity, 98% accuracy
IDH classification cohort	Ratios involving 2-hydroxyglutarate separated 13 IDH-mutant from 24 IDH-wild-type samples
Grade comparisons	Ratios separated 8 grade 2 from 20 grade 4 tumors, and 7 grade 3 from 20 grade 4 tumors
Metabolite ratios calculated	24,492

Key Findings

The method used a sterile syringe plunger to collect tissue, followed by solvent addition and syringe touch spray tandem mass spectrometry.
Researchers compared metabolite ratios rather than individual metabolite signals; the approach was intended to reduce variation from sample collection and changing signal intensity without an internal reference standard.
The N-acetylaspartate-to-carnitine ratio distinguished glioma from nontumor tissue with 97% sensitivity, 100% specificity, and 98% accuracy against clinical diagnoses in the study.
Ratios involving 2-hydroxyglutarate separated IDH-mutant and IDH-wild-type samples in the study cohort; the article notes that mutant IDH is associated with accumulation of 2-hydroxyglutarate.
Selected ratios separated the reported grade 2 and grade 3 groups from grade 4 tumors. Grade 4 tumors had higher alpha-aminoadipate levels, while grade 3 tumors had more 2-hydroxyglutarate than grade 4 tumors.
In mixtures of tumor and normal brain tissue, ratios involving 2-hydroxyglutarate, glutamate, and carnitine generally changed with tumor-cell percentage, but some mixtures with substantial tumor content fell below the tumor-core cutoff.

Clinical Implications

The study authors described the assay as a potential source of molecular information during surgery, particularly when assessing tumor margins, and explicitly stated that it would not replace current standard of care. The mixed-tissue results indicate that thresholds derived from tumor-core tissue may not detect all tumor-containing margin samples.

Conclusion

Syringe touch spray tandem mass spectrometry provided rapid glioma detection and molecular classification in the reported specimen cohort. Its performance at heterogeneous tumor margins remains a limitation identified by the study.